Transfer pricing requires evidence for AMP transactions, functionally reliable comparables, and appropriate aggregation or Berry Ratio benchmarking me...
Revisionary jurisdiction cannot reopen share capital assessments where adequate inquiry supports a permissible view and no independent error is establ...
Reassessment jurisdiction fails where unverified portal information is aggregated without examining the taxpayer's explanation or relevance of entries...
Statutory sanction for delayed reassessment requires approval from the prescribed authority; approval by an inferior authority invalidates jurisdictio...
Transfer pricing margin adjustments require matching treatment of non-operating income and related costs, with comparability issues reconsidered on ev...
Preliminary-expense amortisation and MAT exempt-income adjustments prevailed, while trademark costs and managerial remuneration require fresh verifica...
Export valuation requires contemporaneous evidence; unrelated invoices cannot prove overvaluation, and dual penalties on firm and partner are impermis...
ELFA diagnostic kits were treated as covered by the ELISA exemption because the underlying enzyme-linked immunoassay principle remained the same and only the terminal detection method changed from colourimetric to fluorescence. The Tribunal held that strict construction of exemption entries cannot ignore scientific realities, and applied the genus-species principle and a purposive approach to conclude that technological advancement did not create a separate diagnostic class. It also held that the description of the goods as ELISA kits did not establish wilful suppression or intent to evade duty, so extended limitation was unsustainable. For the relevant period, IGST-related interest and penalty were also held not sustainable.
ELFA diagnostic kits were treated as covered by the ELISA exemption because the underlying enzyme-linked immunoassay principle remained the same and only the terminal detection method changed from colourimetric to fluorescence. The Tribunal held that strict construction of exemption entries cannot ignore scientific realities, and applied the genus-species principle and a purposive approach to conclude that technological advancement did not create a separate diagnostic class. It also held that the description of the goods as ELISA kits did not establish wilful suppression or intent to evade duty, so extended limitation was unsustainable. For the relevant period, IGST-related interest and penalty were also held not sustainable.
Note: It is a system-generated summary and is for quick reference only.